Abstract
Objective To investigate the relationship between expressions of tumor metastasis suppressor gene KAI1/CD82,estrogen receptor and progesterone receptor(ER,PR) in endometrial carcinoma tissues and lymph node metastasis,and study the clinical significance of the relationship between them.Methods The expressions of KAI1,PR and ER of 76 cases from Jan.1998 to Oct.2005 in Gynecological Tumor Department of Tongji Hospital were studied by immunohistochemistry(SP),and assessed under microscopy and analyzed statistically.Results The expressions of KAI1 and PR in endometrial carcinoma tissues were inverse correlated with surgical-pathologic stage,histological grade and depth of myometrial invasion(PKAIl=0.0089、0.0103、0.0356,PPR=0.0026、0.000、0.0053);the expressions of KAI1、PR and ER in tissues involved in lymph node metastasis,cervix-side or adnex were significantly lower than the non-metastasis tissues(PKAIl=0.0091、0.0073,PPR=0.0006、0.0074,PER=0.0129、0.0073);the expression of ER was inverse related to FIGO stage of the tissues(P=0.0226).Among different pathological types of tissues,Only the difference in the expression of PR was of statistical significance(P=0.0446);and the expressions of KAI1,PR and ER were not related to the age of patients and the status of cervix involvement.Under Kaplan Meyer analysis the difference in survival rate was significant statistically(PKAIl=0.0043,PPR=0.0010,PER=0.0124).Logistic regression analysis showed the expression of KAI1 was related to lymph node metastasis(P=0.0400,OR=0.245).The COX proportional hazards regression analysis showed that KAI1,PR and ER were all not the independent prognosis factor to endometrial carcinoma.Conclusion The expression of KAI1 is correlated with the lymph node metastasis,so KAI1 can be used as a predicting indicator of lymph node metastasis and comprehensive assessment in endometrial carcinoma.The important role of KAI1 playing in endometrial carcinoma may be related to PR.The absence of KAI1,PR and ER expressions is closely correlated with the progression,treatment and prognosis of endometrial carcinoma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.